biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Comment by KayakerBCon Feb 01, 2016 5:54pm

225 Views

Post# 24514154

RE:RE:RE:RE:RE:Many early stage biotechs are being sold down to cash

DigiHoller, I see you are now arguing against yourself. What you just posted says...

"....our review of 270+ small-mid cap US biotech stocks suggests that trough valuations have been reached for the US biotechnology sector, with small-mid can EV/cash multiple of 2x, inline with trough values reached in downturns in 2002 and 2008."

That's actually good news for BTI. Our stock price has hardly budged and we're getting the Biotech beatdown out of the way BEFORE we get any license agreements.

We'll be better positioned if we get license agreeements at the Biotech index bottom rather than when it is peaking.

(my bolding)

Bullboard Posts

Options trading in a volatile macro environment